Development of a VesiVax HIV Vaccine Formulation

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: SAM  ON HO
Organization: MOLECULAR EXPRESS, INC.
Fiscal Year: 2021
Award: $299,994
Funding agency: National Institute of Allergy and Infectious Diseases

Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to evaluate the different co-delivery methods of a model HIV antigen using the VesiVax liposomal platform.

Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affinity><Antibody Response><Antigens><Contracting Opportunities><Contracts><Development><HIV><HIV Antigens><HIV vaccine><HIV-Associated Antigens><HIV/AIDS Vaccines><HTLV-III Antigens><HTLV-III-LAV Antigens><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Antigens><LAV Antigens><LAV-HTLV-III><Liposomal><Liposomes><Lymphadenopathy-Associated Antigens><Lymphadenopathy-Associated Virus><Messenger RNA><Methods><Modeling><Non-Polyadenylated RNA><Nucleic Acids><RNA><RNA Gene Products><RNA amplification><Ribonucleic Acid><Virus-HIV><base><develop a vaccine><development of a vaccine><developmental><human immunodeficiency virus vaccine><immunogen><mRNA><monomer><nano particle delivery><nanoparticle delivered><nanoparticle delivery><neutralizing antibody><next generation><particle><vaccine development><vaccine formulation>